From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
|Articles|December 29, 2017
Most Popular Articles of 2017 Highlights SPT Week in Review
Author(s)SPT Staff
Top news of the week from Specialty Pharmacy Times.
Advertisement
4. Top 10 Most Watched SPT Videos of 2017
A review of the most popular video interviews on Specialty Pharmacy Times.
3. DIR Fee Controversy Shaping the Future of Pharmacy
A look back at the debate around direct and indirect remuneration fees in 2017.
2. Top 5 FDA Approvals of Specialty Drugs in 2017
A look at the most read drug approval articles of 2017 covered by Specialty Pharmacy Times.
1. Top 5 Most Read Articles of 2017
A look back at the top articles of the year on Specialty Pharmacy Times.
Advertisement
Related to this article
From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
Phase 3 data show pembrolizumab beats chemotherapy, offering durable first-line control with fewer severe toxicities and chemo-free potential.
In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, discusses NCCN breast cancer guideline updates involving ESR1 mutation testing, targeted therapies, and pharmacists’ roles in monitoring, patient counseling, and treatment access.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
2
The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment
3
Kidney Week 2026: Pharmacists' Growing Role in Kidney Care
4
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
5